Uncle Sam’s Cancer-Fighting Antibodies Up for Licensing Now!
Published Date: 4/3/2026
Notice
Summary
The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
NIH Antibodies Available To License
The NIH is offering government-owned human antibodies (HHS Ref. No. E-025-2025; U.S. Provisional Patent 63/787,190 filed April 11, 2025) for companies to license and commercialize. The technology is pre-clinical and includes a potent antibody (NIH58.9) that killed B cells at 0.01 nanomolar, which companies can license under federal technology-transfer rules.
Potential New Treatments For B-Cell Diseases
The NIH antibodies may be developed into treatments for B-cell cancers, organ transplantation uses, and autoimmune conditions such as lupus and multiple sclerosis. The technology is described as pre-clinical and includes an antibody (NIH58.9) that killed B cells at 0.01 nanomolar, and it 'may be used as treatments' or engineered into bispecifics or antibody-drug conjugates.
Confidential Disclosure Agreement Needed
If you want unpublished details about the NIH antibody invention, you must sign a Confidential Disclosure Agreement (CDA) before receiving copies of unpublished information. Contact Benjamin Hurley at the NIAID Technology Transfer Office to request licensing information.
Foreign Patents May Extend Market Coverage
The notice says foreign patent applications are filed on selected inventions to extend market coverage and those foreign rights may also be available for licensing. This can help licensees access non-U.S. markets using government-filed patent protection.
Collaborative Research Opportunities Offered
NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize the antibody technology (reference E-025-2025). Interested parties should contact the listed Technology Transfer Office representative.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in